Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials
Clin J Am Soc Nephrol. 2024 Apr 16. doi: 10.2215/CJN.0000000000000470. Online ahead of print.NO ABSTRACTPMID:38622766 | DOI:10.2215/CJN.0000000000000470 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - April 16, 2024 Category: Urology & Nephrology Authors: Robert A Fletcher William G Herrington Rajiv Agarwal Kaitlin J Mayne Clare Arnott Meg J Jardine Kenneth W Mahaffey Vlado Perkovic Natalie Staplin David C Wheeler Glenn M Chertow Hiddo J L Heerspink Brendon L Neuen Source Type: research
Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Pulmonary hypertension due to left heart disease (PH-LHD) currently lacks targeted therapies, while Pulmonary arterial hypertension (PAH), despite approved treatments, carries considerable residual risk. Metabolic dysfunction has been linked to the pathogenesis and prognosis of PH through various studies, with emerging metabolic agents offering a potential avenue for improving patient outcomes. (Source: Respiratory Medicine)
Source: Respiratory Medicine - April 14, 2024 Category: Respiratory Medicine Authors: Taimin Luo, Hui Wu, Wanlong Zhu, Liaoyun Zhang, Yilan Huang, Xuping Yang Source Type: research
SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome
Chin Med J (Engl). 2024 Apr 10. doi: 10.1097/CM9.0000000000003108. Online ahead of print.NO ABSTRACTPMID:38602155 | DOI:10.1097/CM9.0000000000003108 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - April 11, 2024 Category: General Medicine Authors: Huixuan Wu Junaid Iqbal Long Li Hongli Jiang Chen Chao Meibiao Zhang Ou Li Houde Zhou Source Type: research
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Nefrologia (Engl Ed). 2024 Apr 10:S2013-2514(24)00069-5. doi: 10.1016/j.nefroe.2024.03.011. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was early appearent that these drugs increased erythropoietin levels and erythropoiesis, and improved iron...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - April 11, 2024 Category: Urology & Nephrology Authors: Aleix Cases Secundino Cigarr án Jos é Luis Górriz Julio Nu ñez Source Type: research
SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome
Chin Med J (Engl). 2024 Apr 10. doi: 10.1097/CM9.0000000000003108. Online ahead of print.NO ABSTRACTPMID:38602155 | DOI:10.1097/CM9.0000000000003108 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - April 11, 2024 Category: General Medicine Authors: Huixuan Wu Junaid Iqbal Long Li Hongli Jiang Chen Chao Meibiao Zhang Ou Li Houde Zhou Source Type: research
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Nefrologia (Engl Ed). 2024 Apr 10:S2013-2514(24)00069-5. doi: 10.1016/j.nefroe.2024.03.011. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was early appearent that these drugs increased erythropoietin levels and erythropoiesis, and improved iron...
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - April 11, 2024 Category: Urology & Nephrology Authors: Aleix Cases Secundino Cigarr án Jos é Luis Górriz Julio Nu ñez Source Type: research
SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome
Chin Med J (Engl). 2024 Apr 10. doi: 10.1097/CM9.0000000000003108. Online ahead of print.NO ABSTRACTPMID:38602155 | DOI:10.1097/CM9.0000000000003108 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - April 11, 2024 Category: General Medicine Authors: Huixuan Wu Junaid Iqbal Long Li Hongli Jiang Chen Chao Meibiao Zhang Ou Li Houde Zhou Source Type: research
Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study
Glycogen storage disease type Ib (GSD Ib) is a rare disorder characterized by impaired glucose homeostasis caused by mutations in the SLC37A4 gene. It is a severe inherited metabolic disease associated with hypog... (Source: Orphanet Journal of Rare Diseases)
Source: Orphanet Journal of Rare Diseases - April 11, 2024 Category: Internal Medicine Authors: Yong-Xian Shao, Cui-Li Liang, Ya-Ying Su, Yun-Ting Lin, Zhi-Kun Lu, Rui-Zhu Lin, Zhi-Zi Zhou, Chun-Hua Zeng, Chun-Yan Tao, Zong-Cai Liu, Wen Zhang and Li Liu Tags: Research Source Type: research
Heart failure management with β-blockers: can we do better?
Curr Med Res Opin. 2024;40(sup1):43-54. doi: 10.1080/03007995.2024.2318002. Epub 2024 Apr 10.ABSTRACTHeart failure (HF) is associated with disabling symptoms, poor quality of life, and a poor prognosis with substantial excess mortality in the years following diagnosis. Overactivation of the sympathetic nervous system is a key feature of the pathophysiology of HF and is an important driver of the process of adverse remodelling of the left ventricular wall that contributes to cardiac failure. Drugs which suppress the activity of the renin-angiotensin-aldosterone system, including β-blockers, are foundation therapies for the...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Mucio Tavares de Oliveira Rui Baptista Sergio A Chavez-Leal Marcely Gimenes Bonatto Source Type: research
The highlights of dialysis in 2023
Nephrol Ther. 2024 Apr 11;20(S1):5-15. doi: 10.1684/ndt.2024.66.ABSTRACTThere has been a wealth of new developments in dialysis this year with the publication of several trials relating to dialysis technique, physical activity and the use of new dialysis treatments. Quality of life should be assessed and managed in all dialysis patients. Lowering the temperature of the dialysis bath in the MyTemp trial does not appear to have an effect on mortality and cardiovascular events. High volume convective hemodiafiltration currently represents the reference technique in hemodialysis; the Convince study confirms its superiority in ...
Source: Nephrologie and Therapeutique - April 10, 2024 Category: Urology & Nephrology Authors: Stanislas Bataille C éline Nodimar Source Type: research
Heart failure management with β-blockers: can we do better?
Curr Med Res Opin. 2024;40(sup1):43-54. doi: 10.1080/03007995.2024.2318002. Epub 2024 Apr 10.ABSTRACTHeart failure (HF) is associated with disabling symptoms, poor quality of life, and a poor prognosis with substantial excess mortality in the years following diagnosis. Overactivation of the sympathetic nervous system is a key feature of the pathophysiology of HF and is an important driver of the process of adverse remodelling of the left ventricular wall that contributes to cardiac failure. Drugs which suppress the activity of the renin-angiotensin-aldosterone system, including β-blockers, are foundation therapies for the...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Mucio Tavares de Oliveira Rui Baptista Sergio A Chavez-Leal Marcely Gimenes Bonatto Source Type: research
The highlights of dialysis in 2023
Nephrol Ther. 2024 Apr 11;20(S1):5-15. doi: 10.1684/ndt.2024.66.ABSTRACTThere has been a wealth of new developments in dialysis this year with the publication of several trials relating to dialysis technique, physical activity and the use of new dialysis treatments. Quality of life should be assessed and managed in all dialysis patients. Lowering the temperature of the dialysis bath in the MyTemp trial does not appear to have an effect on mortality and cardiovascular events. High volume convective hemodiafiltration currently represents the reference technique in hemodialysis; the Convince study confirms its superiority in ...
Source: Nephrologie and Therapeutique - April 10, 2024 Category: Urology & Nephrology Authors: Stanislas Bataille C éline Nodimar Source Type: research
The highlights of dialysis in 2023
Nephrol Ther. 2024 Apr 11;20(S1):5-15. doi: 10.1684/ndt.2024.66.ABSTRACTThere has been a wealth of new developments in dialysis this year with the publication of several trials relating to dialysis technique, physical activity and the use of new dialysis treatments. Quality of life should be assessed and managed in all dialysis patients. Lowering the temperature of the dialysis bath in the MyTemp trial does not appear to have an effect on mortality and cardiovascular events. High volume convective hemodiafiltration currently represents the reference technique in hemodialysis; the Convince study confirms its superiority in ...
Source: Nephrologie and Therapeutique - April 10, 2024 Category: Urology & Nephrology Authors: Stanislas Bataille C éline Nodimar Source Type: research
The highlights of dialysis in 2023
Nephrol Ther. 2024 Apr 11;20(S1):5-15. doi: 10.1684/ndt.2024.66.ABSTRACTThere has been a wealth of new developments in dialysis this year with the publication of several trials relating to dialysis technique, physical activity and the use of new dialysis treatments. Quality of life should be assessed and managed in all dialysis patients. Lowering the temperature of the dialysis bath in the MyTemp trial does not appear to have an effect on mortality and cardiovascular events. High volume convective hemodiafiltration currently represents the reference technique in hemodialysis; the Convince study confirms its superiority in ...
Source: Nephrologie and Therapeutique - April 10, 2024 Category: Urology & Nephrology Authors: Stanislas Bataille C éline Nodimar Source Type: research
The highlights of dialysis in 2023
Nephrol Ther. 2024 Apr 11;20(S1):5-15. doi: 10.1684/ndt.2024.66.ABSTRACTThere has been a wealth of new developments in dialysis this year with the publication of several trials relating to dialysis technique, physical activity and the use of new dialysis treatments. Quality of life should be assessed and managed in all dialysis patients. Lowering the temperature of the dialysis bath in the MyTemp trial does not appear to have an effect on mortality and cardiovascular events. High volume convective hemodiafiltration currently represents the reference technique in hemodialysis; the Convince study confirms its superiority in ...
Source: Nephrologie and Therapeutique - April 10, 2024 Category: Urology & Nephrology Authors: Stanislas Bataille C éline Nodimar Source Type: research
